CASI Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CASI Nasdaq 2836 www.casipharmaceuticals.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - Nov 14th, 2025 2:05 pm
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ - Nov 10th, 2025 2:05 pm
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference - Nov 4th, 2025 7:00 am
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting - Nov 3rd, 2025 7:01 am
CASI Pharmaceuticals Appoints James Huang to Board of Directors - Sep 26th, 2025 7:45 am
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study - Sep 8th, 2025 7:00 am
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference - Sep 3rd, 2025 7:00 am
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors - Sep 2nd, 2025 7:00 am
CASI Pharmaceuticals Second Quarter 2025 Earnings: Misses Expectations - Aug 31st, 2025 7:29 am
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results - Aug 29th, 2025 2:05 pm
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025 - Aug 28th, 2025 7:00 am
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates - Aug 14th, 2025 7:15 am
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - Aug 12th, 2025 4:25 pm
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates - Aug 7th, 2025 3:55 pm
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - Aug 6th, 2025 6:55 am
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR) - Aug 4th, 2025 7:00 am
Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates - Jul 31st, 2025 6:15 am
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program - Jul 21st, 2025 2:05 pm
CASI Pharmaceuticals Provides Business and Clinical Update - May 19th, 2025 7:00 am
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results - May 16th, 2025 6:00 am